#1 Clinical Trials Search in Europe

Tenecteplase

Tenecteplase, a thrombolytic drug, is being extensively studied in clinical trials for its potential in treating acute ischemic stroke. These trials aim to evaluate its efficacy, safety, and optimal dosing compared to standard treatments. Researchers are exploring its use in various time windows after stroke onset and in combination with other therapies like endovascular thrombectomy.

Table of Contents

What is Tenecteplase?

Tenecteplase is a medication used to treat certain types of blood clots that can cause serious health problems. It belongs to a class of drugs called thrombolytics or “clot-busters”[1]. Tenecteplase is also known by the brand names Metalyse and TNKase[2][3]. Another common name for this drug is TNK-tPA, which stands for Tenecteplase Tissue Plasminogen Activator[4].

How Does Tenecteplase Work?

Tenecteplase works by breaking down blood clots that have formed in blood vessels. It is a genetically engineered version of a natural protein in the body that helps dissolve clots. Tenecteplase is designed to be more effective at targeting and breaking down clots compared to older thrombolytic medications[5].

What Conditions Does Tenecteplase Treat?

Tenecteplase is primarily used to treat two serious medical conditions:

  • Acute Ischemic Stroke: This is a type of stroke caused by a blood clot blocking blood flow to part of the brain. Tenecteplase can help dissolve the clot and restore blood flow, potentially reducing brain damage[1][6].
  • Acute Myocardial Infarction: Also known as a heart attack, this occurs when a blood clot blocks blood flow to part of the heart muscle. Tenecteplase can help break down the clot and improve blood flow to the heart[2][3].

How is Tenecteplase Administered?

Tenecteplase is given as a single intravenous (IV) injection. This means it is injected directly into a vein. The dose is usually based on the patient’s weight. One of the advantages of Tenecteplase is that it can be given as a quick single injection over 5-10 seconds, unlike some other clot-busting drugs that require longer infusions[7][8].

For stroke treatment, Tenecteplase is typically given within 4.5 hours of when stroke symptoms first appear. Some research is looking at whether this time window can be extended in certain cases[6][5].

Effectiveness of Tenecteplase

Research has shown that Tenecteplase can be effective in treating both strokes and heart attacks. For strokes, studies have found that Tenecteplase may be at least as effective as the standard clot-busting drug alteplase, and possibly more effective in certain types of strokes[7][8].

The effectiveness of Tenecteplase is often measured by improvements in patients’ symptoms and functioning. For stroke patients, this might include better scores on scales that measure stroke severity and daily functioning. For heart attack patients, effectiveness can be measured by improved survival rates and heart function[2][3].

Safety and Side Effects

Like all medications, Tenecteplase can have side effects. The most serious potential side effect is bleeding, including bleeding in the brain (intracranial hemorrhage). This is because the medication works by breaking down clots, which can sometimes lead to unwanted bleeding[1][8].

Other possible side effects can include:

  • Bleeding at other sites in the body
  • Allergic reactions
  • Low blood pressure
  • Nausea

Doctors carefully weigh the potential benefits and risks before giving Tenecteplase. Patients are closely monitored after receiving the medication[2][3].

Ongoing Research on Tenecteplase

Researchers continue to study Tenecteplase to better understand its effectiveness and safety. Some areas of ongoing research include:

  • Comparing different doses of Tenecteplase to find the optimal amount[8]
  • Investigating whether Tenecteplase can be safely used in a wider range of stroke patients, including those who arrive at the hospital later after their stroke symptoms begin[5]
  • Studying the use of Tenecteplase in mobile stroke units, which are ambulances equipped to diagnose and treat strokes[9]
  • Exploring whether Tenecteplase can be used to treat blood clots in other situations, such as in dialysis catheters[10]

These ongoing studies aim to improve our understanding of how to best use Tenecteplase to help patients with strokes, heart attacks, and potentially other conditions caused by blood clots.

Aspect Details
Drug Tenecteplase (TNK-tPA)
Primary Use Treatment of acute ischemic stroke
Administration Single intravenous bolus over 5-10 seconds
Common Doses 0.25 mg/kg or 0.4 mg/kg (max 25 mg or 40 mg)
Time Windows Various, from 4.5 to 24 hours after stroke onset
Main Outcomes Functional independence (mRS), stroke severity reduction (NIHSS), vessel recanalization
Safety Concerns Intracranial hemorrhage, systemic bleeding
Potential Advantages Single bolus administration, potentially higher efficacy in large vessel occlusions
Comparison Often compared to standard treatment (Alteplase) or no thrombolysis
Additional Research Optimal dosing, use in combination with endovascular thrombectomy, extended time windows

FAQ

  • What is Tenecteplase? Tenecteplase is a thrombolytic drug, also known as a 'clot-buster'. It works by dissolving blood clots that cause strokes or heart attacks. In clinical trials, it's being studied as a potential improvement over current standard treatments for acute ischemic stroke.
  • How is Tenecteplase administered? Tenecteplase is typically administered as a single intravenous bolus over 5-10 seconds. The dose is usually weight-adjusted, with common doses in trials being 0.25 mg/kg or 0.4 mg/kg, with maximum doses of 25 mg and 40 mg respectively.
  • What are the potential advantages of Tenecteplase over current treatments? Tenecteplase has several potential advantages. It can be administered as a single bolus, which is more convenient than the current standard treatment (alteplase) that requires an infusion. Some studies suggest it may be more effective in opening blocked blood vessels, especially in patients with large vessel occlusions.
  • What are the main outcomes being measured in Tenecteplase trials? The main outcomes typically include functional independence (often measured by the modified Rankin Scale), reduction in stroke severity (measured by the National Institutes of Health Stroke Scale), rates of successful blood vessel reopening, and safety outcomes such as the occurrence of intracranial hemorrhage.
  • Are there any risks associated with Tenecteplase treatment? As with all thrombolytic treatments, there is a risk of bleeding, particularly intracranial hemorrhage. This risk is carefully monitored in all clinical trials. Other potential side effects may include allergic reactions or systemic bleeding. The trials aim to determine if these risks are lower, similar, or higher compared to current standard treatments.

Ongoing Clinical Trials on Tenecteplase

  • A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • A Study of Tenecteplase for Acute Ischemic Stroke in Patients Taking Direct Oral Anticoagulants

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Finland France Germany The Netherlands +3

  • Study on the Effectiveness of Tenecteplase in Patients with Acute Ischemic Stroke Taking Rivaroxaban, Apixaban, or Edoxaban

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Norway Sweden

  • Study comparing tenecteplase and acetylsalicylic acid in patients with central retinal artery occlusion within 4.

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Denmark Finland Ireland Norway Sweden

  • A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Greece Hungary Norway Romania Spain

  • Comparing tenecteplase and mechanical clot removal versus mechanical clot removal alone for adults with a large ischemic stroke

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Tenecteplase and Alteplase for Patients with Acute Ischemic Stroke Due to Basilar Artery Blockage

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Alteplase for Vision Recovery in Patients with Acute Central Retinal Artery Occlusion

    Not recruiting

    3 1 1
    Investigated drugs:
    Germany

  • Study on the Safety and Effectiveness of Tenecteplase for Patients with Acute Ischemic Stroke and Incomplete Reperfusion After Mechanical Thrombectomy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Finland Germany The Netherlands Portugal

Glossary

  • Acute Ischemic Stroke: A sudden interruption in the blood supply to the brain, typically caused by a blood clot, leading to a lack of oxygen and potential brain damage.
  • Thrombolysis: A treatment to dissolve dangerous blood clots in blood vessels, improve blood flow, and prevent damage to tissues and organs.
  • Tenecteplase (TNK-tPA): A genetically modified form of tissue plasminogen activator (tPA) used as a thrombolytic drug to break down blood clots in acute ischemic stroke and heart attacks.
  • Alteplase: The current standard thrombolytic drug used for treating acute ischemic stroke, administered as an infusion over 1 hour.
  • Modified Rankin Scale (mRS): A scale from 0 to 6 used to measure the degree of disability in patients who have had a stroke. Lower scores indicate better outcomes.
  • National Institutes of Health Stroke Scale (NIHSS): A tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between 0 and 4. A higher score indicates a more severe stroke.
  • Endovascular Thrombectomy (EVT): A minimally invasive procedure used to remove a blood clot from a blood vessel in the brain in patients with acute ischemic stroke.
  • Symptomatic Intracranial Hemorrhage (sICH): Bleeding within the skull that is associated with clinical worsening of the patient's condition, a major safety concern in stroke treatment.
  • Recanalization: The restoration of blood flow to an area of the brain that was previously blocked by a clot.
  • Time Window: The period after the onset of stroke symptoms during which a treatment is considered potentially effective and safe to administer.

References

  1. https://clinicaltrials.gov/study/NCT05281549
  2. https://clinicaltrials.gov/study/NCT02206646
  3. https://clinicaltrials.gov/study/NCT02191670
  4. https://clinicaltrials.gov/study/NCT01654445
  5. https://clinicaltrials.gov/study/NCT06010628
  6. https://clinicaltrials.gov/study/NCT04752631
  7. https://clinicaltrials.gov/study/NCT06320431
  8. https://clinicaltrials.gov/study/NCT03340493
  9. https://clinicaltrials.gov/study/NCT06498323
  10. https://clinicaltrials.gov/study/NCT00396253